Treanda (Bendamustine HCl) Patent Expiration, LOE Window & CMS Spending
Treanda (Bendamustine HCl) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2029-09-26 (last listed 2031-04-26), 0 AB generics, $2.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N022249 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-09-26 |
| Last Listed Patent or Exclusivity Date | 2031-04-26 |
| Orange Book Patents (*PED Extensions) | 18 patents (9 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $2.8M |
| 2024 Medicare Part D Spend | $1.6M |
| 2024 Medicaid Spend | $1.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.